Package Insert: Information for the User
Montelukast KERN PHARMA 4 mg Chewable Tablets EFG
Read this package insert carefully before starting to take the medication.
1. What Montelukast Kern Pharma is and for what it is used
2. Before taking Montelukast Kern Pharma
3. How to take Montelukast Kern Pharma
4. Possible adverse effects
5. Storage of Montelukast Kern Pharma
6. Additional information
Montelukast Kern Pharma is a leukotriene receptor antagonist that blocks certain substances called leukotrienes. Leukotrienes produce narrowing and swelling of the airways in the lungs. By blocking leukotrienes, montelukast improves asthma symptoms and helps control asthma.
Your doctor has prescribed Montelukast Kern Pharma to treat your child's asthma and prevent asthma symptoms during the day and night.
The dosage of Montelukast will depend on your child's symptoms and the severity of their asthma, as determined by your doctor.
What is asthma?
Asthma is a chronic disease.
Asthma includes:
Asthma symptoms include: Coughing, wheezing, and congestion in the chest.
Inform your child's doctor about any allergy or medical condition your child has now or has had.
Do not give Montelukast Kern Pharma to your child if
Be especially careful with Montelukast Kern Pharma
Several neuropsychiatric events (e.g., changes in behavior and mood-related changes, depression, and suicidal tendencies) have been reported in patients of all ages treated with montelukast (see section 4). If you develop these symptoms while taking montelukast, you should contact your doctor. |
Use of other medications
Some medications may affect the functioning of Montelukast, or Montelukast may affect the functioning of other medications your child is using.
Inform your doctor or pharmacist if you are using or have recently used other medications, including those obtained without a prescription.
Before taking Montelukast, inform your doctor if your child is taking the following medications:
Taking Montelukast Kern Pharma with food and beverages
Montelukast Kern Pharma should not be taken with meals; it should be taken at least 1 hour before or 2 hours after eating.
Pregnancy and breastfeeding
This subsection is not applicable to Montelukast Kern Pharma 4 mg, as its use is indicated in children aged 2 to 5 years, however, the following information is important for the active ingredient, montelukast.
Use during pregnancy
Women who are pregnant or intend to become pregnant should consult their doctor before taking Montelukast. Your doctor will evaluate whether you can take montelukast during this period.
Use during breastfeeding
The passage of montelukast into breast milk is unknown. If you are breastfeeding or intend to breastfeed, you should consult your doctor before taking Montelukast Kern Pharma.
Driving and operating machinery
This subsection is not applicable to Montelukast Kern Pharma 4 mg, as its use is indicated in children aged 2 to 5 years, however, the following information is important for the active ingredient, montelukast.
Montelukast Kern Pharma is not expected to affect your ability to drive a car or operate machinery. However, individual responses to the medication may vary. Certain adverse effects (such as dizziness and somnolence) that have been reported rarely with montelukast may affect the patient's ability to drive or operate machinery.
Important information about some of the components of Montelukast Kern Pharma
The chewable tablets of Montelukast Kern Pharma contain aspartame, a source of phenylalanine. If your child has phenylketonuria (a rare hereditary disorder of metabolism), you should be aware that each 4 mg chewable tablet contains phenylalanine (equivalent to 0.674 mg of phenylalanine in each 4 mg chewable tablet).
For children aged 2 to 5 years:
A daily chewable tablet of 4 mg should be taken at night. Montelukast should not be taken with meals; it should be taken at least 1 hour before or 2 hours after eating.
Make sure your child does not take any other medication that contains the same active ingredient, montelukast.
For children aged 2 to 5 years, Montelukast Kern Pharma 4 mg chewable tablets are available.
For children aged 6 to 14 years, Montelukast Kern Pharma 5 mg chewable tablets are available.
Montelukast chewable tablets are not recommended for children under 2 years of age.
If your child takes more Montelukast Kern Pharma than they should:
Seek help from your child's doctor immediately.
In most cases of overdose, no adverse effects were reported. The symptoms that were most frequently reported in adults and children who experienced an overdose were abdominal pain, drowsiness, drowsiness, headache, vomiting, and hyperactivity.
If you forgot to give Montelukast Kern Pharma to your child:
Try to give Montelukast Kern Pharma as prescribed. However, if your child forgets a dose, simply resume the usual regimen of one tablet once a day.
Do not give a double dose to make up for the missed dose.
If your child stops taking Montelukast Kern Pharma:
Montelukast Kern Pharma can only treat your child's asthma if they continue to take it.
It is essential that your child continues to take montelukast for the duration prescribed by their doctor. It will help control your child's asthma.
If you have any other questions about using this product, ask your child's doctor or pharmacist.
Like all medicines, Montelukast Kern Pharma can cause side effects, although not everyone will experience them.
In clinical trials conducted with montelukast 4 mg, the side effects related to the administration of the medication and reported most frequently (occurring in at least 1 in 100 patients and less than 1 in 10 patients treated), were:
In addition, the following side effects were reported in clinical trials with montelukast 10 mg and 5 mg:
These side effects were generally mild and occurred more frequently in patients treated with montelukast than with placebo (a tablet that does not contain medication).
In addition, since the medication has been marketed, the following side effects have been reported:
In patients with asthma treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, tingling or numbness of arms and legs, worsening of respiratory symptoms, and/or skin rash (Churg-Strauss syndrome) have been reported. Inform your doctor immediately if your child has one or more of these symptoms.
Ask your doctor or pharmacist for more information about side effects. If you consider that any of the side effects you are experiencing are severe or if you notice any side effect not mentioned in this prospectus, report it to your doctor or pharmacist.
Montelukast Kern Pharma Composition
Product Appearance and Packaging Contents
Montelukast Kern Pharma 4 mg chewable tablets are pink, oval, biconvex. They are presented in blister packaging in a 28-tablet container.
Marketing Authorization Holder
KERN PHARMA, S.L.
Polígono Ind. Colón II
Venus, 72
08228 Terrassa (Barcelona)
Spain
Responsible for Manufacturing
PHARMATEN S.A.
Dervenakion 6
Pallini 15351
Attica (Greece)
This leaflet was approved in May 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.